News | February 21, 2025
Wanbury reports 88% drop in Q3 FY25 PAT
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
the inspection conducted from January 27 to January 31, 2025
The Alathur facility specializes in the production of Cephalosporin antibiotics
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
This rating reflects Lupin's leadership in environmental transparency and performance
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Subscribe To Our Newsletter & Stay Updated
